heart diseas lead caus mortal morbid world biomark need diagnosi prognosi therapeut monitor risk stratif acut injuri acut myocardi infarct ami chronic diseas heart failur the procedur biomark develop involv discoveri valid translat clinic practic panel candid protein monitor risk heart diseas two type biomark possibl heartspecif cardiovascular pulmonari system monitor marker here review use process cardiac biomark discoveri valid proteom analysi cardiac myocyt tissu serum plasma exampl use biomark discoveri given which albumin bind protein subproteom examin use malditof addition exampl protein valid given use affin surfac enhanc laser desorpt ioniz seldi monitor diseaseinduc posttransl modif ternari status myoctyeorigin protein cardiac troponin serum

Brian A. Stanley

Rebekah L. Gundry

Robert J. Cotter

Jennifer E. Van Eyk

Heart Disease, Clinical Proteomics and Mass Spectrometry

diabet mellitus complex multisystem disord may classifi autoimmun mediat type 1 diabet insulin resist associ type 2 diabet type 1 diabet select loss beta cell within endocrin islet consequ tcell cytokin mediat destruct cell perhap conjunct destruct periislet schwann cell type 2 diabet etiolog resist rang from postreceptor defect insulin signal pathway excess product adipocyt deriv cytokin antagon insulin action mitochondri defect interfer glucos dispos proteom base technolog provid new insight defect

Murray Korc

Update on Diabetes Mellitus

George M. Kunz

Daniel W. Chan

The Use of Laser Capture Microscopy in Proteomics Research &#x2013; A Review

the identif autoantibodi tumor cell protein proteom approach has great potenti impact cancer biomark discoveri the humor immun respons repres form biolog amplif signal otherwis weak due veri low concentr antigen especi earli stage cancer addit proteom can detect immunoreact direct against protein posttransl modif twodimension gel base western blot protein antigen microarray multiplex elisa reaction have been appli our group antigen base biomark detect valid the latter two base liquidphas separ suitabl autom this work has result identif numer cancer biomark candid larg clinic studi current plan establish valu earli cancer diagnosi

Yuji Imafuku

Gilbert S. Omenn

Samir Hanash

Proteomics Approaches to Identify Tumor Antigen Directed Autoantibodies as Cancer Biomarkers

identifi use marker cancer can problemat due limit amount sampl some sampl nippl aspir fluid naf earlystag tumor inher small other sampl serum collect larger volum archiv sampl veri valuabl onli small amount each sampl may avail singl studi also given divers natur cancer inher variabl individu protein level seem like best approach screen cancer determin profil batteri protein result major challeng identifi protein marker diseas abil screen mani protein use veri small amount sampl review outlin some technolog advanc proteom great advanc capabl specif propos strategi identifi marker breast cancer naf util mass spectrometri simultan screen hundr thousand protein each sampl the best potenti marker identifi analysi can extens character use elisa microarray assay becaus microarray analysi quantit larg number sampl can effici analyz approach offer abil rapid assess batteri select protein manner direct relev tradit clinic assay

Richard C. Zangar

Susan M. Varnum

Chandice Y. Covington

Richard D. Smith

A Rational Approach for Discovering and Validating Cancer Markers in Very Small Samples Using Mass Spectrometry and ELISA Microarrays

Karin D. Rodland

Mass Spectrometry and Biomarker Development

the human proteom organiz hupo plasma proteom project has mount pilot phase focuss key problem essenti standard specimen collect specimen handl choic fraction analysi technolog search engin databas protein identif this intern collabor lay groundwork mani largescal clinic epidemiolog studi health diseas

Advancement of Biomarker Discovery and Validation through the HUPO Plasma Proteome Project

About this journal

Disease Markers publishes papers related to the identification of disease markers, the elucidation of their role and mechanism, as well as their application in the prognosis, diagnosis and treatment of diseases.

Journal profile

Meet the editorial board

Chief Editor Paola Gazzaniga is an Associate Professor in the Department of Molecular Medicine at Sapienza University of Rome, Italy. Her core research focuses on liquid biopsies in patients with solid tumors.

Editor spotlight

Submit to Special Issue

We currently have a number of Special Issues open for submission. Special Issues highlight emerging areas of research within a field, or provide a venue for a deeper investigation into an existing research area.

Special Issues

Author guidelines

Editorial board

Databases and indexing

title

Disease Markers publishes papers related to the identification of disease markers, the elucidation of their role and mechanism, as well as their application in the prognosis, diagnosis and treatment of diseases.

description

https://images.hindawi.com/journals/dm/dm.banner.jpg

twitter:card

twitter:description

twitter:site

twitter:title

twitter:url

twitter:image

Disease Markers | Hindawi

Disease Markers

This Issue is now open for submissions.
Papers are published upon acceptance, regardless of the Special Issue publication date.

Disease Markers

Mass Spectrometry and Biomarker Development

Mass Spectrometry and Biomarker Development

Articles

Heart Disease, Clinical Proteomics and Mass Spectrometry

Update on Diabetes Mellitus

The Use of Laser Capture Microscopy in Proteomics Research – A Review

Proteomics Approaches to Identify Tumor Antigen Directed Autoantibodies as Cancer Biomarkers

A Rational Approach for Discovering and Validating Cancer Markers in Very Small Samples Using Mass Spectrometry and ELISA Microarrays

Mass Spectrometry and Biomarker Development

Advancement of Biomarker Discovery and Validation through the HUPO Plasma Proteome Project